Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management

American Journal of Hematology

Volumn 89, Issue 9, 2014, Pages 915-925

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CALRETICULIN; EVEROLIMUS; FEDRATINIB; GANDOTINIB; HEMOGLOBIN; JANUS KINASE 2; JANUS KINASE INHIBITOR; LESTAURTINIB; MOMELOTINIB; PACRITINIB; POMALIDOMIDE; RUXOLITINIB; UNCLASSIFIED DRUG; XL 019;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ANEMIA; ARTICLE; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DIFFERENTIAL DIAGNOSIS; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM PLUS; ERYTHROCYTE TRANSFUSION; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; HYDROXYUREA REFRACTORY SPLENOMEGALY; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKOCYTE COUNT; LOW RISK PATIENT; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

BONE MARROW; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY MYELOFIBROSIS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; WORLD HEALTH ORGANIZATION;

EID: 84906053853     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23703     Document Type: Article

References (95)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951. Prepublished on 2009/04/10 as DOI 10.1182/blood-2009-03-209262.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
4. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014. Prepublished on 2014/01/21 as DOI 10.1038/leu.2014.35.
5. Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014;28:431-433. Prepublished on 2013/10/08 as DOI 10.1038/leu.2013.286.
6. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-1963.
7. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012;26:1135-1137. Prepublished on 2011/11/09 as DOI 10.1038/leu.2011.320.
8. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
9. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.
10. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005;105:973-977.
11. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
12. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438.
13. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-69.
14. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: Literature review and discussion. Eur J Haematol 2009;82:329-338.
15. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014. Prepublished on 2014/01/10 as DOI 10.1038/leu.2014.3.
16. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
17. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979;43:185-190.
18. Tefferi A, Pardanani A. Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 2014. Prepublished on 2014/02/12 as DOI 10.1038/nrclinonc.2014.16.
19. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29:3179-3184. Prepublished on 2011/07/13 as DOI 10.1200/JCO.2010.34.5298.
20. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: A distinct entity? Leuk Res 2001;25:829-838.
21. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review. Br J Haematol 2014. Prepublished on 2014/01/29 as DOI 10.1111/bjh.12756.
22. Orazi A, O'Malley DP, Jiang J, et al. Acute panmyelosis with myelofibrosis: An entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005;18:603-614.
23. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
24. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
25. Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115:496-499.
26. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011;25:82-88. Prepublished on 2010/10/15 as DOI leu2010234 [pii]10.1038/leu.2010.234.
27. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2009;85:14-17.
28. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of International Prognostic Scoring System and Dynamic International Prognostic Scoring System. Haematologica 2011;96:167-170.
29. Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010;84:105-108.
30. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397. Prepublished on 2010/12/15 as DOI JCO.2010.32.2446 [pii] 10.1200/JCO.2010.32.2446.
31. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011;118:4595-4598. Prepublished on 2011/09/02 as DOI 10.1182/blood-2011-08-371096.
32. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010;24:105-109.
33. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-761.
34. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483.
35. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26:475-480. Prepublished on 2011/09/14 as DOI 10.1038/leu.2011.253.
36. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227-5234. Prepublished on 2011/09/17 as DOI blood-2011-06-363424 [pii] 10.1182/blood-2011-06-363424.
37. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-4171. Prepublished on 2012/09/13 as DOI 10.1182/blood-2012-05-429696.
38. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869. Prepublished on 2013/04/27 as DOI 10.1038/leu.2013.119.
39. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients. Leukemia 2011;25:1834-1839. Prepublished on 2011/06/22 as DOI 10.1038/leu.2011.161.
40. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
41. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 2012;30:1087-1094. Prepublished on 2012/02/15 as DOI 10.1200/JCO.2011.39.0310.
42. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-1363. Prepublished on 2011/02/09 as DOI 10.1200/JCO.2010.32.9490.
43. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014. Prepublished on 2014/02/06 as DOI 10.1038/leu.2014.57.
44. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients. Leukemia 2014. Prepublished on 2014/02/20 as DOI 10.1038/leu.2014.76.
45. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009;27:5587-5593.
46. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
47. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010;116:2857-2858.
48. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053. Prepublished on 2013/11/01 as DOI 10.1182/blood-2013-02-485888.
49. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012;366:844-846. Prepublished on 2012/03/02 as DOI 10.1056/NEJMe1115119.
50. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths. Blood 2012;119:2721-2730. Prepublished on 2012/01/27 as DOI 10.1182/blood-2011-11-395228.
51. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-1457. Prepublished on 2011/10/15 as DOI 10.1056/NEJMc1109555.
52. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-367.
53. Silverstein MN. Agnogenic Myeloid Metaplasia. Acton, MA: Publishing Science Group; 1975. p 126.
54. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007;13:377-383.
55. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-296.
56. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106:1974-1984.
57. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
58. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-1164.
59. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-4766.
60. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83:154-155.
61. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007;21:1827-1828.
62. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010;89:1233-1237.
63. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001;97:1896.
64. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264-5270.
65. Deeg HJ, Appelbaum FR. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood 2011;117:7185. Prepublished on 2011/07/02 as DOI 117/26/7185 [pii]10.1182/blood-2011-04-349142.
66. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30.
67. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-455.
68. DeAngelo DJ, Spencer A, Fischer T, et al. Activity of oral panobinostat (LBH589) in patients with myelofibrosis. ASH Annual Meeting Abstracts 2009;114:2898.
69. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-4569.
70. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-304. Prepublished on 2010/11/06 as DOI 10.1038/leu.2010.254.
71. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-130. Prepublished on 2010/01/07 as DOI 10.1002/ajh.21598.
72. Tefferi A, Passamonti F, Barbui T, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence. Blood 2013;122:394.
73. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
74. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-1191. Prepublished on 2011/10/29 as DOI 10.4065/mcp.2011.0518.
75. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807. Prepublished on 2012/03/02 as DOI 10.1056/NEJMoa1110557.
76. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798. Prepublished on 2012/03/02 as DOI 10.1056/NEJMoa1110556.
77. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis? Blood 2013;122:3843-3844. Prepublished on 2013/11/30 as DOI 10.1182/blood-2013-10-531103.
78. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-796. Prepublished on 2011/01/12 as DOI 10.1200/JCO.2010.32.8021.
79. Pardanani A, Harrison CN, Cortes JE, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122:393.
80. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-1327. Prepublished on 2013/03/06 as DOI 10.1038/leu.2013.71.
81. Pardanani A, Gotlib J, Gupta V, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013;122:108.
82. Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 2011;118:282.
83. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-2076. Prepublished on 2011/07/05 as DOI 10.1182/blood-2011-01-330563.
84. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000;95:2226-2233. Prepublished on 2000/03/25.
85. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-370.
86. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998;91:3630-3636.
87. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-511. Prepublished on 1998/11/25.
88. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: Associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003;78:1223-1233. Prepublished on 2003/10/09 as DOI 10.4065/78.10.1223.
89. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;118:813-816. Prepublished on 2002/08/16.
90. Neben-Wittich MA, Brown PD, Tefferi A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol 2010;85:808-810. Prepublished on 2010/08/28 as DOI 10.1002/ajh.21819.
91. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010;85:192-199. Prepublished on 2010/06/10 as DOI 10.1111/j.1600-0609.2010.01480.x.
92. Feldman LS, Demyttenaere SV, Polyhronopoulos GN, Fried GM. Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. J Laparoendosc Adv Surg Tech A 2008;18:13-19.
93. Iwase K, Higaki J, Mikata S, et al. Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. Surg Laparosc Endosc Percutan Tech 1999;9:197-202.
94. Hiatt JR, Gomes AS, Machleder HI. Massive splenomegaly. Superior results with a combined endovascular and operative approach. Arch Surg 1990;125:1363-1367.
95. Hocking WG, Machleder HI, Golde DW. Splenic artery embolization prior to splenectomy in end-stage polycythemia vera. Am J Hematol 1980;8:123-127.